It has now been shown that a drug used to control blood sugar in people with diabetes helps prevent or relieve kidney disease, creating millions of deaths each year and requiring hundreds of thousands of people to use dialysis to stay alive. 19659002] Doctors say that it is difficult to mitigate the importance of this study, and what it means to prevent this problem, growing due to the epidemic of obesity
The study tested a Janssen Invokana drug Pharmaceuticals. The results of Sunday were discussed at a medical meeting in Australia and published by the New England Journal of Medicine.
Diabetes has about 30 million Americans and more than 420 million people worldwide, and most of them are type 2, which is linked to obesity. It happens when the body can not make enough insulin or use properly, which turns food into its energy.
This can damage your kidneys over time, causing disease and ultimately failure. In the US, it is responsible for nearly half a million people who need dialysis, and thousands of kidney transplants every year.
Some blood pressure drugs reduce this risk but are only partially effective. The new study tested Invokana, a daily pill now sold to help control blood sugar, to see if it could help prevent kidney disease when it is added to standard treatments.
For the study, about 1
The people who had the drug had a 30% lower risk – kidney failure, the need for dialysis, the need for kidney transplantation, death from kidney or heart causes, or other symptoms that were failing the kidney.
For every 1,000 people who took the drug for 2.5 years, 47 fewer cases would exist
The rates of serious side effects were similar to the drug and placebo groups including leg tightening, leg or toe, anxiety that emerged with a previous study of Invokana. There was one side effect, when the body cannot produce enough insulin, more often among the people on Invokana but very overall.
Janssen, who is part of Johnson & Johnson, sponsored the study and has many authors working or consulting with the company. The drug costs about $ 500 a month in the United States. Out of pocket costs can be different, depending on insurance.
It is not possible to over-estimate the importance of this major study and this good work. Julie Ingelfinger and Clifford Rosen, editors of the medical journal, wrote in an accompanying article.
In recent years, a number of studies have found that Invokana and some similar drugs can lower heart risks. The new results, showing that Invokana can fail the kidneys to stop or prevent, extend the potential benefits of the drug.
Marilynn Marchione can be followed by http://twitter.com/MMarchioneAP
Associate Department of Health and Science receives support from the Department of Science Education Institute Medical Howard Hughes. The AP is solely responsible for all matters.